Commercialization: Page 7
-
From the fringes to the forefront — the mRNA era has taken hold of pharma
A look at what’s next for the industry’s buzziest technology.
By Kim Ribbink • April 22, 2022 -
Profile
For Global Blood Therapeutics, the connection to sickle cell disease runs deep
An underserved patient population is a guiding light for the company, which recently scored a new approval.
By Robin Robinson • April 19, 2022 -
Q&A
How pharma can up its social media game
Health Union’s VP of community development, Sara Hayes, discusses how pharma marketers can better reach online patient communities.
By Karissa Waddick • April 18, 2022 -
How Congress could play a role in personalized medicine
PGx — a tool to help determine proper dosing — may be poised to achieve broader use in healthcare and pharma.
By Kelly Bilodeau • April 11, 2022 -
Optinose CEO senses big opportunities for the company's nasal delivery device
Peter Miller explains how a repackaged sinus drug has won late-stage clinical success.
By Jared Whitlock • April 11, 2022 -
Q&A
Time-saving tech lights Alcon's path into digital innovation
Kevin Yapp, global head or omni-channel transformation at the Swiss eye health company shares why the customer should be a North Star when developing digital tools.
By Kim Ribbink • April 4, 2022 -
Podcast
Woman of the Week: Daré Bioscience's Sabrina Martucci Johnson
The CEO is setting a path to transform women’s health at an opportune time.
By Taren Grom • March 30, 2022 -
Profile
From media to menopause: Creating new spaces in women's telehealth
Why the former editor-in-chief of Marie Claire abandoned her magazine career to create a menopause-focused women's health startup.
By Alexandra Pecci • March 29, 2022 -
How a rock 'n' roll guru is putting a new spin on health education for patients
A former agent for The Rolling Stones has launched a healthcare streaming platform with a cast of entertainment heavyweights — and he wants pharma to be a headline act.
By Meagan Parrish • March 28, 2022 -
Q&A
Why Astellas is adopting a 'focus area approach' to partnerships
Chief Strategy Officer, Naoki Okamura, explains why new trends and innovations require a different approach to alliances.
By Kim Ribbink • March 22, 2022 -
Virpax's CEO on leveraging new formulations to move drugs toward approval
Anthony Mack shares his lessons from getting unconventional pharma products across the finish line.
By Meagan Parrish • March 18, 2022 -
Podcast
Woman of the Week: Ceek Women's Health CEO Fahti Khosrowshahi
Fahti Khosrowshahi, CEO and founder, Ceek Women’s Health, is designing award-winning products to change the face of women's health.
By Taren Grom • March 16, 2022 -
Q&A // Biotech Spotlight
Liquid biopsy is a multibillion-dollar market, and InterVenn is looking to take advantage
The company’s CEO explains how its liquid biopsy tests target a unique, untapped layer of biology.
By Taren Grom • March 14, 2022 -
Profile
From angel to operator: The unlikely journey of Endevica Bio's CEO
Russell Potterfield is honing his new found passion for the space to guide Endevica into the clinic.
By Jared Whitlock • March 9, 2022 -
Podcast
Woman of the Week: Sumitovant's Chief Business Development and Commercial Officer Adele Gulfo
Adele Gulfo, chief business development and commercial officer at Sumitovant Biopharma, is leaning into her decades of experience to bring a future-focused approach to drug development.
By Taren Grom • Feb. 23, 2022 -
Eisai's mission to shake off Aduhelm's shadow and bring another AD drug to market
The company's senior VP of clinical research on how they're building off the science of Aduhelm to develop better Alzheimer's treatments.
By Kelly Bilodeau • Feb. 23, 2022 -
Podcast
Woman of the Week: Organon's Chief Commercial Officer Susanne Fiedler
Susi Fiedler, chief commercial officer, was instrumental in the spinout of Organon as a standalone company focused on a broad range of women’s health issues.
By Taren Grom • Feb. 16, 2022 -
Profile
How Veru is developing blockbuster drugs while avoiding biotech's 'valley of death'
Why sexual health and telemedicine are key to the company's goals in oncology.
By Meagan Parrish • Feb. 16, 2022 -
Opinion
Industry executives on the milestone moments shaping pharma's future
Scientific, technological, and communication changes that are making a permanent impact on the industry.
By Taren Grom • Feb. 9, 2022 -
Podcast
Woman of the Week: Syneos Health's president of commercial solutions, Michelle Keefe
How Michelle Keefe, president, commercial solutions at Syneos Health, steered her team into a rapid pivot during the pandemic.
By Taren Grom • Feb. 2, 2022 -
What the opera can teach pharma about patient communication
With his opera knowledge, Inozyme’s Director of Investor Relations Stefan Riley uses his unique perspective to tell the company's compelling story.
By Kim Ribbink • Jan. 23, 2022 -
Opinion
Pharma execs reveal the industry's most pressing issues
Several market factors — including COVID — are driving changes and trends in the industry.
By Taren Grom • Jan. 14, 2022 -
Welcome to the new PharmaVoice
A similar mission, a new format, and our plans for PharmaVoice's next chapter.
By Davide Savenije • Jan. 13, 2022 -
Letter from the Editor
Gratitude A simple thank you feels entirely inadequate to express our gratitude to you — our thought leaders, partners, and readers — for trusting us to be your forum for the exchange of ideas, perspectives, and insights over the past 20-plus years. Thank you to the more than 20,000 of you who ha...
By Taren Grom • Nov. 15, 2021 -
Upfront
Glen de Vries In MEMORIAM On Nov. 11, 2021, the world lost a healthcare visionary and trailblazer when Glen de Vries, 49, co-CEO of Medidata, died in a plane crash in New Jersey. Most recently, Glen fulfilled a lifelong dream in October 2021, as a member of the Blue Origin NS-18 crew, going into ...
By PharmaVoice Team • Nov. 15, 2021